Traws Pharma Announces Up to \$60 Million Private Placement Financing to Advance Influenza Program
Traws Pharma Announces Up to \$60 Million Private Placement Financing to Advance Influenza Program
Key Points of the Announcement
- Traws Pharma, Inc. (NASDAQ: TRAW) has entered into a securities purchase agreement for a private investment in public equity (“PIPE”), expected to provide approximately \$10 million in gross proceeds at closing, with up to an additional \$50 million from milestone-based and three-year warrants.
- The financing is led by Sirenia Capital Management, LP, with participation from both new and existing institutional and accredited investors.
- The capital will be used primarily to advance Traws Pharma’s influenza program, including a planned human challenge trial for tivoxavir marboxil in the United Kingdom.
- Cantor Fitzgerald & Co. acted as lead placement agent, with Citizens JMP Securities, LLC and Tungsten Advisors LLC (through Finalis Securities LLC) as co-placement agents.
- The securities are being sold in a private placement and are not registered under the Securities Act of 1933, though the company has agreed to file a resale registration statement with the SEC.
Details of the Financing Structure
- The April 2026 PIPE financing consists of:
- \$10 million in upfront gross proceeds at a purchase price of \$1.6730 per share for common stock (or pre-funded warrants).
- Series A milestone-based warrants: Up to an additional \$10 million, exercisable upon receipt of approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct the human challenge trial.
- Series B milestone-based warrants: Up to another \$10 million, exercisable following both shareholder approval and the announcement of data from the challenge trial.
- Series C three-year warrants: Up to \$30 million, exercisable following shareholder approval.
- All warrants are priced “at-the-market” under NASDAQ rules, with exercise prices equal to the deal price.
- The financing was completed on April 15, 2026, with funding expected on April 16, 2026, subject to customary closing conditions.
Strategic and Price-Sensitive Implications for Shareholders
- This financing enables Traws Pharma to fully fund its pivotal influenza human challenge trial in the UK, a critical milestone for the company’s lead asset, tivoxavir marboxil.
- The structure of the financing—with significant amounts contingent on achieving key regulatory and clinical milestones—means that future capital infusions are directly tied to the company’s progress. This aligns incentives and reduces dilution unless the company achieves these milestones.
- The warrants, if exercised, could bring in up to an additional \$50 million, which would provide substantial runway for further development, but also could result in significant dilution for existing shareholders depending on warrant take-up.
- The company is also actively seeking partners for its legacy oncology programs (rigosertib and narazaciclib), which could yield additional sources of revenue or non-dilutive funding.
- Regulatory risk remains: Traws Pharma’s IND for tivoxavir marboxil is currently on clinical hold with the FDA, and the company’s ability to advance clinical trials and unlock further financing is dependent on regulatory clearance and successful outcomes in the UK challenge trial.
- Investors should be aware that the offer and sale of these securities is not a public offering, and the securities are not registered under the Securities Act unless or until a registration statement becomes effective.
About Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company developing novel therapies targeting critical respiratory viral threats, including seasonal and H5N1 influenza and COVID-19/Long COVID. Its lead asset, tivoxavir marboxil, is in development as a once-monthly oral prophylactic for influenza, with potential as a single-dose therapy for both seasonal and avian flu. The company’s COVID-19 asset, ratutrelvir, is a ritonavir-independent oral antiviral. Traws is also seeking partners for its legacy oncology assets.
Forward-Looking Statements
This article contains forward-looking statements regarding the company’s business, financing, and clinical development plans. These statements are subject to risks and uncertainties, including satisfaction of closing conditions, achievement of warrant-triggering milestones, regulatory outcomes, and capital needs. Actual results may differ materially. Investors should review Traws Pharma’s filings with the SEC for a full discussion of risk factors.
Contact Information
Disclaimer: This article is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The information is based on public disclosures by Traws Pharma as of April 15, 2026, and may contain forward-looking statements subject to significant risks and uncertainties. Investors should undertake their own due diligence and consult with their financial advisors before making investment decisions.
View Traws Pharma, Inc. Historical chart here
